Overview

DMT210 Topical Gel in the Treatment of Acne Rosacea

Status:
Completed
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.
Phase:
Phase 2
Details
Lead Sponsor:
Dermata Therapeutics